Method and composition for the topical treatment of diabetic neuropathy
AssigneeThe Quigley Corporation
InventorRichard Allen Rosenbloom
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Quigley Corporation
InventorRichard Allen Rosenbloom
Estimating the term…
A method and composition for the treatment of diabetic neuropathy is disclosed. The composition comprises a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant formulated in a pharmaceutically acceptable carrier. It has been found that this combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In view of the consensus in the art that effective combinations of various active agents have not been demonstrated to be effective for the treatment of diabetic neuropathy, the present invention provides a surprising and unexpected effect. In addition, the topical compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment, In a second aspect, a method for the topical administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is topically administered to the areas of the body that have been adversely affected by the diabetic neuropathy on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms and at least some recover of the damaged nerve tissues.
A topical composition for the treatment of diabetic neuropathy by application to the skin, which comprises a cold compounded mixture of an amount of a compound that promotes synthesis of nerve growth factor which is effective when administered topically to the skinto promote synthesis of nerve growth factor, an amount of an aldose reductase inhibitor which is effective when administered topically to the skin to inhibit aldose reductase and an effective amount of an antioxidant, formulated in a pharmaceutically acceptable carrier for a topical composition.
Dependencies are inferred from the claim text.